Correlations Between Ultrasonographic Findings of Invasive Lobular Carcinoma of the Breast and Intrinsic Subtypes.
Sign Up to like & getrecommendations! Published in 2018 at "Ultraschall in der Medizin"
DOI: 10.1055/a-0715-1668
Abstract: PURPOSE To analyze the ultrasonographic findings of invasive lobular carcinoma (ILC) of the breast in 360 women and the correlations between the characteristics and the intrinsic subtypes. MATERIALS AND METHODS We evaluated the imaging findings… read more here.
Keywords: findings invasive; invasive lobular; lobular carcinoma; ultrasonographic findings ... See more keywords
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials
Sign Up to like & getrecommendations! Published in 2018 at "Acta Oncologica"
DOI: 10.1080/0284186x.2017.1401735
Abstract: Abstract Background: The study of the intrinsic molecular subtypes of breast cancer has revealed differences among them in terms of prognosis and response to chemotherapy and endocrine therapy. However, the ability of intrinsic subtypes to… read more here.
Keywords: chemotherapy; breast; radiotherapy; breast cancer ... See more keywords
Abstract P1-06-02: Characterization of gene- and sample-level APOBEC mutagenesis enrichment with respect to intrinsic subtypes, tumor mutational burden, and immune composition in breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-p1-06-02
Abstract: Introduction: APOlipoprotein B mRNA Editing enzyme Catalytic peptide-like, APOBEC, is a family of innate immune enzymes that catalyze cytosine to uracil deamination in single-stranded DNA, which lead to mutations in preferred trinucleotide contexts. APOBEC mutagenesis… read more here.
Keywords: cancer; apobec mutagenesis; intrinsic subtypes; breast cancer ... See more keywords
Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.580
Abstract: 580Background: NSABP B-41, randomly assigned 529 patients with HER2 positive breast cancer to receive neoadjuvant trastuzumab, lapatinib, or the combination, with weekly paclitaxel following doxorubicin and cyclophosphamide x 4. No significant difference in pCR was… read more here.
Keywords: her2 positive; breast; positive breast; breast cancer ... See more keywords